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Background: Pompe disease has a broad clinical spectrum, in which the phenotype is partially explained by the
genotype. The aim of this study was to describe phenotypical variation among siblings with non-classic Pompe disease.
We hypothesized that siblings and families with the same genotype share more similar phenotypes than the total
population of non-classic Pompe patients, and that this might reveal genotype-phenotype correlations.
Methods: We identified all Dutch families in which two or three siblings were diagnosed with Pompe disease and
described genotype, acid α-glucosidase activity, age at symptom onset, presenting symptoms, specific clinical features,
mobility and ventilator dependency.
Results: We identified 22 families comprising two or three siblings. All carried the most common mutation c.-32-13 T >
G in combination with another pathogenic mutation. The median age at symptom onset was 33 years (range 1–
62 years). Within sibships symptom onset was either in childhood or in adulthood. The median variation in symptom
onset between siblings was nine years (range 0–31 years). Presenting symptoms were similar across siblings in 14 out
of 22 families. Limb girdle weakness was most frequently reported. In some families ptosis or bulbar weakness were
present in all siblings. A large variation in disease severity (based on wheelchair/ventilator dependency) was observed
in 11 families. This variation did not always result from a difference in duration of the disease since a third of the less
affected siblings had a longer course of the disease. Enzyme activity could not explain this variation either. In most
families male patients were more severely affected. Finally, symptom onset varied substantially in twelve families
despite the same GAA genotype.
Conclusion: In most families with non-classic Pompe disease siblings share a similar phenotype regarding symptom
onset, presenting symptoms and specific clinical features. However, in some families the course and severity of disease
varied substantially. This phenotypical variation was also observed in families with identical GAA genotypes. The
commonalities and differences indicate that besides genotype, other factors such as epigenetic and environmental
effects influence the clinical presentation and disease course.
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Pompe disease (OMIM 232300: acid maltase deficiency or
glycogen storage disease type II) is an autosomal recessive
disorder caused by a deficiency of acid α-glucosidase which
leads to accumulation of glycogen in various tissues. The
deficiency is caused by mutations in the acid α-glucosidase
(GAA) gene (OMIM 606800) [1-7]. The combination of
mutations in the GAA gene determines the phenotype to a
certain extent [8,9]. A heteroallelic combination of two se-
vere mutations that results in a complete enzyme defi-
ciency causes classic infantile Pompe disease. Soon after
birth these infants present with generalized hypotonia,
hypertrophic cardiomyopathy, feeding difficulties and re-
spiratory problems. If not treated they usually die before
the age of one year [4,10,11]. If one of the two mutations is
not fully deleterious and some residual enzyme activity re-
mains, the disease can manifest at anytime during child-
hood or adulthood. This is referred to as non-classic
Pompe disease and patients develop slowly progressive
limb girdle weakness and respiratory problems [12,13].
Thus, the GAA genotype is the first level at which clinical
heterogeneity arises.
In the Netherlands, about 95% of adult patients with
Pompe disease and 68% of affected children under 18 years
have the mild and common mutation c.-32-13 T >G in
one GAA allele combined with a far more severe mutation
in the other allele. c.-32-13 T >G is a so called ‘leaky
splice’ mutation, producing only 5-15% of the normal
amount of messenger RNA and resulting in a proportional
amount of structurally and functionally normal acid α-
glucosidase [8,14]. The phenotype of patients with one c.-
32-13 T >G mutation combined with a fully deleterious
mutation varies widely in age of symptom onset and rate
of disease progression despite the similar GAA genotype
and haplotype [14,15]. Since siblings with Pompe disease
are genetically more identical than non-relatives, we as-
sumed that they would develop more similar phenotypes.
Some phenotypical variation within affected families has
been described in case reports [16-21].
The aims of our study were to describe the phenotyp-
ical variation in a large group of families, to determine
to what extent the disease in siblings and families with
the same GAA genotype had the same clinical presenta-




In the Netherlands, all patients diagnosed with Pompe
disease are referred to Erasmus MC University Medical
Centre, which is the national centre of expertise for this
orphan disease. For our study we identified all families
with non-classic Pompe disease in which two or three
siblings were affected. We used the definition of non-classic Pompe disease as described in a previously pub-
lished letter [13]. Patients with non-classic Pompe dis-
ease have onset of symptoms in childhood or adulthood.
Onset of symptoms can also be in the first year of life,
however, these patients do not have persisting and pro-
gressive cardiac hypertrophy such as in classic infantile
Pompe disease. In literature, non-classic Pompe disease
is also referred as late-onset Pompe disease, although
onset of disease can also be in childhood. All patients
were seen between October 2004 and December 2012.
The Medical Ethical Committee of Erasmus University
Medical Center approved the study protocols.
Enzyme and mutation analyses
Enzyme activity in fibroblasts was measured with 4-
methylumbelliferyl-α-D-glucopyranoside (4-MU) as sub-
strate [14]. GAA sequence analyses were performed
using genomic DNA isolated from white blood cells as
previously described [22,23].
Clinical features
At the first visit, a thorough medical history was obtained.
Patients were asked at what age they first experienced
symptoms and what the nature of these symptoms was.
The duration of the disease was calculated from the onset
of symptoms to the current age of the patient. Distribution
of weakness and specific symptoms such as ptosis, bulbar
weakness and scapular winging were recorded. Where ap-
plicable, the age at start of wheelchair or ventilator use
was recorded.
Statistical analyses
The data were analysed using SPSS 20. Descriptive statis-
tics were used for all calculations and data are presented
as medians with ranges. The following parameters were
assessed whether they had an influence on the phenotyp-
ical variation in and/or between families: disease duration,




Among a total of 126 patients with Pompe disease cared
for at our centre, we identified 23 families with two or
three affected siblings. Because in one family a patient was
already wheelchair dependent due to other causes, we did
not include this family in our analyses. The common c.-
32-13 T >G mutation was encountered in all families; in
12 families in combination with c.525delT (r.0), and in 10
families with another equally detrimental second mutation
[24]. Four patients from different families died before they
were referred to our centre and these patients were not in-
cluded because of lack of data. The remaining 22 families
comprised 50 patients. The median age at first visit was
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ing treated with enzyme replacement therapy (ERT) at this
time. The characteristics of the study population are pre-
sented in Table 1.
Symptom onset and clinical features
Figure 1 gives an overview of the disease course of each
family: from symptom onset, to the age of diagnosis and
the age siblings became wheelchair or ventilator dependent.
The youngest patient developed symptoms in the first year
of life, while the oldest patient developed symptoms at the
age of 62 years. The median difference in symptom onset
was nine years between siblings (range 0–31 years). All sib-
lings within a family developed first symptoms either in
childhood (4/22) or in adulthood (18/22). The age of diag-
nosis varied between 0 and 72 years (median 39 years). The
median delay between symptom onset and diagnosis was
four years (range 0–43 years) for all patients. The median
time between diagnosis of the first sibling and of the second
or third family member was one year (range 0–19 years).
Table 2 shows the similarities and differences in clinical
characteristics within families. In 13 families all siblings
presented with skeletal muscle weakness (i.e. limb girdle
weakness or delayed motor development). In one family
all three siblings presented with a combination of limb gir-
dle weakness and bulbar weakness. Bulbar weakness com-
prised dysarthria, dysphagia and chewing difficulties. InTable 1 Patient characteristicsa
Total
Patients 50
Gender: males (%) 24 (48)
Median age at symptom onset in years (range)b 33 (1–62)
Median age at diagnosis in years (range)c 39 (0–72)
Current median age in years (range) 53 (5–79)
Mobility (%)
▪ Ambulant 30 (60)
▪ Walking aids 6 (12)
▪ Wheelchair-dependent 14 (28)
Ventilator-dependent (%) 14 (28)
α-Glucosidase activity in fibroblasts (nmol MU/mg.h)d 13 (8–18)
Families 22
Families with genotype (%)
▪ c.-32-13 T > G/c.525delT (r.0) 12 (55)
▪ c.-32-13 T > G/c.378_379del (p.Cys127LeufsX18) 2 (9)
▪ c.-32-13 T > G/c.925G > A (p.Gly309Arg) 2 (9)
▪ c.-32-13 T > G/other pathogenic mutation 6 (27)
aData are numbers with percentages or medians with ranges. bThe median
age at onset of symptoms is calculated for 47 patients because three patients
are asymptomatic. cOne patient was diagnosed at birth because she had a
brother with Pompe disease, but she was asymptomatic. dControl range
40–180 nmol MU/mg.h.the eight remaining families there was a variation in the na-
ture of first symptoms, including three families with a pre-
symptomatic sibling (only enzyme and genetic diagnosis,
no clinical signs). Specific clinical features seen throughout
the course of disease such as ptosis, bulbar weakness and
scapular winging were clustered within some families.
Severity of the disease and possible influencing factors
As shown in Table 2, in approximately 50% of the families
there was at least one wheelchair or ventilator-dependent
patient. The majority of these wheelchair and/or ventilator-
dependent patients (93% and 86%) had a sibling who was
ambulant and not using ventilator support at the same age
that they became dependent themselves. In one family co-
morbidity played a role in clinical variability between sib-
lings, as one sibling acquired kyphoscoliosis after vertebral
spondylitis and became wheelchair dependent (Figure 1,
family 22). We have added a movie file that illustrates the
marked differences in disease course within some sibships
[see Additional file 1].
In a subgroup of 11 families representing the largest
variation in disease severity, with at least one wheelchair
or ventilator-dependent sibling and one ambulant and
ventilator-independent sibling, we compared the charac-
teristics of the siblings. The most severely affected sibling
had the longest duration of the disease in 64% of these
families. Males were more severely affected than females
in seven families (64%). In the majority of families (60%),
the patient with the highest enzyme activity in fibroblasts
was more severely affected.
Twelve families shared genotype c.-32-13 T > G/
c.525delT (r.0). The onset of symptoms varied substan-
tially between these families with the same set of GAA
mutations (Figure 1); e.g. families 2–4 had symptom on-
set in childhood, while in families 11, 12, 15, 18 and 19
the first symptoms presented later in adulthood.
Discussion
This is the first study that describes phenotypical com-
monalities and variation in a large cohort of families
representing 50 patients with non-classic Pompe disease.
We confirmed the presence of phenotypical commonal-
ities within sibships, including: symptom onset either in
childhood or in adulthood, similar presenting symptoms
(in 70% of families), and the occurrence of particular
symptoms such as ptosis and bulbar weakness. However,
the rate of disease progression varied substantially within
some families and also between families with the same
GAA genotype.
Infants with classic infantile Pompe disease show a
consistent phenotype, also within sibships, while the
clinical spectrum of non-classic Pompe disease is much
more variable regarding onset and progression of the
disease [3,6-8,12]. Since siblings share the same set of










































* c.-32-13T>G / c.525delT
Figure 1 Course of the disease in 22 families with non-classic Pompe disease. Families 1–4 are childhood-onset patients and families 5–22
are adult-onset patients. Each dot represents an event during the course of the disease. Families highlighted with * share the same
GAA genotype.
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non-relatives, we expected to find less variation in
phenotype within sibships compared to the overall
Pompe population. In our 22 Dutch families the present-
ing symptoms were often the same. As limb girdle weak-
ness is known to be the most frequently occuring initial
symptom in Pompe disease, it is not surprising this was
found frequently in all siblings of a family [3,5-7,12].
Other symptoms also seemed to cluster within families.
Remarkably, bulbar weakness was a presenting symptom
in all three siblings of one family. Bulbar weakness has
been reported in approximately 25% of adult Pompe pa-
tients, but rarely as first symptom (1-2%) [6,12,25]. It
was also found in all siblings of a second family but lateron in the course of the disease. The same applies to pto-
sis [26-28]. Ptosis has been reported in 23% of the Dutch
adults with Pompe disease [12]. In our cohort of families
we found the same percentage. In four families ptosis
was present in all siblings. All carried the c-32-13 T > G
mutation, but the second GAA mutation differed be-
tween the families. The same applied to the two families
with bulbar weakness, suggesting a role for (epi)genetic
factors in the clustering of symptoms within families.
We also found differences in phenotype within the same
family. The median difference in symptom onset between
siblings was nine years, with extremes of 20 to 31 years in
three families. Since time of symptom onset was based on
patients reporting their own history, there may be a recall
Table 2 Clinical characteristics within 22 familiesa
Total of families (%)
Presenting symptoms in all siblings (%)
Skeletal muscle weaknessb 13 (59)
Skeletal muscle + bulbar weakness 1 (5)
Variation in first symptomsc 8 (36)
Clinical features (%)
▪ All siblings had a ptosis 4 (18)
▪ All siblings had bulbar weakness 2 (9)
▪ All siblings had scapular winging 1 (5)
Mobility (%)
All siblings were ambulant 11 (50)
One or two siblings were wheelchair-dependentd 10 (45)
All siblings were wheelchair-dependent 1 (5)
Ventilation (%)
▪ None of the siblings was ventilator-dependent 12 (54)
▪ One or two siblings were ventilator-dependentd 9 (41)
▪ All siblings were ventilator-dependent 1 (5)
aData are numbers with percentages. bLimb girdle weakness, delayed motor
development. cIn three families one sibling was still asymptomatic. dIn five
families consisting of three siblings, one or two siblings were wheelchair or
ventilator-dependent, while the other sibling was not.
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time of symptom onset between siblings. However, it is
inevitable that large differences will occur within some
families. The majority of wheelchair and/or ventilator-
dependent patients had an ambulant or non-ventilated
sibling, while they had already been using these supportive
measures when they were the same age. The duration of
the disease (time from symptom onset) could not always
explain this difference, since a third of the patients were
wheelchair or ventilator-dependent and needed these
resources at an earlier stage of their disease than their
ambulant or non-ventilated sibling.
We looked for possible factors explaining the observed
phenotypical variation between siblings. Siblings who had
the disease for longer were often more severely affected.
However, this does not explain why these siblings devel-
oped symptoms at a younger age and why their disease
progressed more rapidly. Gender could play a role since
twice as many males as females were more severely af-
fected. Earlier studies on the natural course of Pompe dis-
ease also show male gender to be a predictive factor for a
more severe respiratory status [12,29]. GAA activity did
not explain differences in phenotype, since in only three
families did the most severely affected patient have the
lowest amount of enzyme activity in fibroblasts. This is in
accordance with previously published data on Pompe pa-
tients, describing the absence of a correlation between the
clinical course and residual activity in patients with the c-32-13 T >G/null genotype [5]. Other co-morbidities con-
tributed to phenotypical differences in only one family.
The substantial differences in age of symptom onset
observed in the 12 families with an identical GAA geno-
type (c.-32-13 T > G/c.525delT (r.0)) suggest that other
factors such as variability in genetic background, modi-
fying genes or environmental factors are likely to play a
role [5,8,14,16,20,30]. An example of a potential modify-
ing gene is the angiotensin-converting enzyme gene,
which has been described as playing a role in modulat-
ing phenotype and prognosis in Pompe disease [31,32].
This and other modifying genes might also explain the
clear differences between families with the same GAA
genotype, and the clustering of symptoms such as ptosis
and bulbar weakness in certain families.
Conclusion
This study in families with non-classic Pompe disease
showed that onset of symptoms within a family appeared
to be either in childhood or adulthood, presenting symp-
toms of siblings were often similar and some specific clin-
ical features clustered in certain families. However, the
course and severity of disease can vary substantially within
some families and between families with the same GAA
genotype. This phenotypical consistency and variation
within sibships indicates that other factors such as epigen-
etic and environmental effects influence the course of
clinical disease. Additional studies are needed to identify
these factors and to determine which prognostic factors
will predict the disease course.
Additional file
Additional file 1: This movie illustrates the marked difference in
disease course between two siblings who are both 70 years old.
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